Search

A study conducted by researchers from the University of Vermont has found that the TV005 dengue vaccine candidate provides protection against dengue serotypes 2 and 3. The study involved two controlled human infection trials, where participants were vaccinated with TV005 and then challenged with either the dengue 2 or dengue 3 virus. The vaccine was well-tolerated and protected all vaccinated individuals from infection with the targeted serotypes. This research contributes to the development of an effective dengue vaccine, which is crucial in addressing the global health threat posed by dengue viruses. [Extracted from the article]